| Cat. No. |
Product Name |
Information |
| PC-62680 |
NSC 625987
CDK4 inhibitor
|
NSC 625987 is a potent, selective CDK4 inhibitor with IC50 of 0.2 uM, displays >500-fold selectivity over CDK2 (IC50 >100 uM for cdc2/cyclin A, cdk2/cyclin A and cdk2/cyclin E). |
| PC-62678 |
Ryuvidine
CDK4 inhibitor, SETD8 inhibitor
|
Ryuvidine is a potent, selective CDK4 inhibitor with IC50 of 6.0 uM, displays >30-fold selectivity over CDK2 (IC50>100 uM). |
| PC-62677 |
PNU-112455A
CDK2/5 inhibitor
|
PNU-112455A is an ATP-competitive CDK2/5 inhibitor with Ki of 2 uM and 2 uM for cdk2·GST-cyclin E and cdk5·GST-p25 respectively, shows no activity against c-Met, IGR-1R, and ERK2. |
| PC-62573 |
CDK5 inhibitor 20-223
CDK5 inhibitor
|
CDK5 inhibitor 20-223 (CP 668863) potent, selective, ATP-competitive CDK2/5 inhibitor with IC50 of 6.0 and 8.8 nM for CDK2/CyclinE and CDK5/p35, with little to no activity against CDK1/4/6/7/9. |
| PC-62561 |
CCT068127
CDK2/9 inhibitor
|
CCT068127 (CCT68127) is a novel potent inhibitor of CDK2 and CDK9 with IC50 of 10 and 90 nM for CDK2/E and CDK9/T, respectively. |
| PC-62534 |
IIIM-290
CDK2/9 inhibitor
|
IIIM-290 (IIIM290) is a potent, orally active cyclin-dependent kinase (CDK) inhiitor with IC50 of 1.9 and 16 nM for Cdk-9/T1 and Cdk-2/A, respectively. |
| PC-62302 |
THZ531
CDK12/13 inhibitor
|
THZ531 (THZ-531) is a first-in-class, selective CDK12 and CDK13 covalent inhibitor with IC50 of 158 nM and 69 nM, respectively. |
| PC-61917 |
BS-194
CDK2 inhibitor
|
BS-194 (BS194) is a potent, selective, orally bioactive CDK2 inhibitor with IC50 of 2.4 nM, displays 140-fold selectivity over CDK7 (IC50=378 nM). |
| PC-61916 |
Samuraciclib
CDK7 inhibitor
|
ICEC0942 (Samuraciclib, CT7001) is a potent, selective, orally active CDK7 inhibitor with IC50 of 41 nM, displays 15-fold selectivity over CDK2 (IC50=578 nM). |
| PC-61659 |
SEL120-34A hydrochloride
CDK8/19 inhibitor
|
Romaciclib (SEL120-34A, SEL120) hydrochloride is an ATP-competitive, selective, orally active CDK8/19 inhibitor that inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50 of 4.4 nM and 10.4 nM, respectively. |
| PC-61658 |
SEL120-34A
CDK8/19 inhibitor
|
Romaciclib (SEL120-34A) is an ATP-competitive, selective, orally active CDK8/19 inhibitor that inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50 of 4.4 nM and 10.4 nM, respectively. |
| PC-61405 |
AZ5576
CDK9 inhibitor
|
AZ5576 (AZ-5576) is a potent, highly selective, and orally bioavailable inhibitor of CDK9 with IC50 of < 5 nM, decreases phosphorylation of Ser2-RNAPII in cells with an IC50 of 96 nM. |
